TB Research

Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant <i>Rv0678</i> Mutant in a Mouse Model of Tuberculosis

Deepak Almeida, Paul J. Converse, Si-Yang Li, Anna M. Upton, Nader Fotouhi, Eric L. Nuermberger

Antimicrobial Agents and Chemotherapy · 2021-09

Abstract

Bedaquiline (BDQ, B) is the first-in-class diarylquinoline to be approved for treatment of tuberculosis (TB). Recent guidelines recommend its use in treatment of multidrug- and extensively drug-resistant tuberculosis (MDR/XDR-TB).

MeSH terms

  • Bedaquiline
  • Tuberculosis
  • Medicine
  • Mutant
  • Mycobacterium tuberculosis
  • Virology
  • Mutation
  • Microbiology
  • Biology
  • Drug resistance